Repeated ketamine doses elevate superoxide dismutase activity in a pharmacological model of schizophrenia-like phenotypes in mice

Abstract

This study evaluated behavioral phenotypes and superoxide dismutase (SOD) enzymatic activity in a repeated sub-anesthetic dose of ketamine (KET) administered to model schizophrenia in an animal study. The animals were divided into three (3) experimental groups. The KET alone group received sub-anesthetic dose of KET (20 mg/kg) for 14 consecutive days. The control group vehicle (VEH) received distilled water (10 mL/kg) as a VEH, while the KET and risperidone (RISP) group (KET + RISP) received a sub-anesthetic dose of KET (20 mg/kg) alone for 7 consecutive days, followed by RISP (0.5 mg/kg) administered 1-h post-KET treatment from days 8 to 14. All treatments were administered intraperitoneally (i.p.). Twenty-four hours after the last treatment, behavioral phenotypes (locomotor activity and cognition) were assessed using the locomotor activity cage and the elevated plus maze (EPM). Thereafter, SOD enzymatic activity was evaluated in homogenized brain tissue from each mouse using spectrophotometric analysis. Animals that received KET (20 mg/kg i.p) alone showed a significant (P < 0.05) increase in movement counts and rearing events in the locomotor activity test. It also prolonged the latency to enter the open arms during the anxiety-induced cognitive assessment in the EPM, compared to animals that received distilled water or those that received KET and RISP. SOD enzymatic activity was significantly elevated in the KET group compared to the VEH and KET + RISP groups. The elevated SOD enzymatic activity may represent a compensatory response to the oxidative stress induced by repeated sub-anesthetic doses of KET.

Keywords

Superoxide dismutase / KetamineSchizophrenia / Phenotypes / Mice / Model

Funding

None.

Conflict of interest

The authors declare that they have no competing interests.

References

[1] Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008; 11(6):851-876. doi: 10.1017/S1461145707008401

[2] Murray AJ, Rogers JC, Katshu MZUH, Liddle PF, Upthegrove R. Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders. Front Psychiatry. 2012;12:703452. doi: 10.3389/fpsyt.2021.703452

[3] Dudzińska E, Szymona K, Bogucki J, et al. Increased markers of oxidative stress and positive correlation low-grade inflammation with positive symptoms in the first episode of schizophrenia in drug-naïve patients. J Clin Med. 2022; 11(9):2551. doi: 10.3390/jcm11092551

[4] Padurariu M, Ciobica A, Dobrin I, Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett. 2010; 479(3):317-320. doi: 10.1016/j.neulet.2010.05.088

[5] Parise EM, Alcantara LF, Warren BL, et al. Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats. Biol Psychiatry. 2013; 74(10):750-759. doi: 10.1016/j.biopsych.2013.04.027

[6] Usman Y, Aderibigbe AO, Benneth BA, Fehintola FA. Antipsychotic effects of ethanol extract of Blighia sapida (Sapindaecea) stem bark in pharmacological models of psychosis in Swiss mice. Afr J Med Med Sci. 2019;48:151-160.

[7] Uliana DL, Zhu X, Gomes FV, Grace AA. Using animal models for the studies of schizophrenia and depression: The value of translational models for treatment and prevention. Front Behav Neurosci. 2022;16:935320. doi: 10.3389/fnbeh.2022.935320

[8] Krystal JH, D’Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl). 2003; 169(3-4):215-233. doi: 10.1007/s00213-003-1582-z

[9] Driesen NR, McCarthy G, Bhagwagar Z, et al. The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacology. 2013; 38(13):2613-2622. doi: 10.1038/npp.2013.170

[10] Muthukumaraswamy SD, Shaw AD, Jackson LE, Hall J, Moran R, Saxena N. Evidence that sub-anesthetic doses of ketamine cause sustained disruptions of NMDA and AMPA-Mediated frontoparietal connectivity in humans. J Neurosci. 2015; 35(33):11694-11706. doi: 10.1523/JNEUROSCI.0903-15.2015

[11] Lindefors N, Barati S, O’Connor WT. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Res. 1997; 759(2):205-212. doi: 10.1016/S0006-8993(97)00255-2

[12] Cadinu D, Grayson B, Podda G, Harte MK, Doostdar N, Neill JC. NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology. 2018; 142:41-62. doi: 10.1016/j.neuropharm.2017.11.045

[13] Jürgenson M, Aonurm-Helm A, Zharkovsky A. Behavioral profile of mice with impaired cognition in the elevated plus-maze due to a deficiency in neural cell adhesion molecule. Pharmacol Biochem Behav. 2010; 96(4):461-468. doi: 10.1016/j.pbb.2010.07.006

[14] Kokkinou M, Ashok AH, Howes OD. The effects of ketamine on dopaminergic function: Meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry. 2018; 23(1):59-69. doi: 10.1038/mp.2017.190

[15] Frohlich J, Van Horn JD. Reviewing the ketamine model for schizophrenia. J Psychopharmacol. 2014; 28(4):287-302. doi: 10.1177/0269881113512909

[16] Malik JA, Yaseen Z, Thotapalli L, Ahmed S, Shaikh MF, Anwar S. Understanding translational research in schizophrenia: A novel insight into animal models. Mol Biol Rep. 2023; 50(4):3767-3785. doi: 10.1007/s11033-023-08241-7

[17] Behrens MM, Ali SS, Dao DN, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 2007; 318(5856):1645-1647. doi: 10.1126/science.1148045

[18] Koju N, Qin Z, Sheng R. Reduced nicotinamide adenine dinucleotide phosphate in redox balance and diseases: A friend or foe? Acta Pharmacol Sin. 2022;43:1889-1904. doi: 10.1038/s41401-021-00838-7

[19] Wang Y, Branicky R, Noë A, Hekimi S. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. J Cell Biol. 2018; 217(6):1915-1928. doi: 10.1083/jcb.201708007

[20] Stojković T, Radonjić NV, Velimirović M, et al. Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 39:192-199. doi: 10.1016/j.pnpbp.2012.06.013

[21] Lang X, Wang DM, Du XD, et al. Elevated activity of plasma superoxide dismutase in never-treated first-episode schizophrenia patients: Associated with depressive symptoms. Schizophrenia Res. 2020; 222:291-296. doi: 10.1016/j.schres.2020.05.032

[22] Ben-Azu B, Aderibigbe AO, Ajayi AM, Iwalewa EO. Neuroprotective effects of the ethanol stem bark extracts of Terminalia ivorensis in ketamine-induced schizophrenia-like behaviors and oxidative damage in mice. Pharm Biol. 2016; 54(12):2871-2879. doi: 10.1080/13880209.2016.1190382

[23] Yan BC, Park JH, Ahn JH, et al. Neuroprotection of post-treatment with risperidone, an atypical antipsychotic drug, in rat and gerbil models of ischemic stroke and the maintenance of antioxidants in a gerbil model of ischemic stroke. J Neurosci Res. 2014; 92:795-807. doi: 10.1002/jnr.23360

[24] Puech C, Badran M, Runion AR, et al. Explicit memory, anxiety and depressive like behavior in mice exposed to chronic intermittent hypoxia, sleep fragmentation, or both during the daylight period. Neurobiol Sleep Circadian Rhythms. 2022;13:100084. doi: 10.1016/j.nbscr.2022.100084

[25] Ben-Azu B, Aderibigbe AO, Adeoluwa OA, Iwalewa EO. Ethanol extracts of Terminalia ivorensis (Chev A.)stem bark attenuates the positive, negative and cognitive symptoms of psychosis in experimental animal models. Br J Pharm Res. 2016;12:1-14. doi: 10.9734/BJPR/2016/28629

[26] Ben-Azu B, Adebayo OG, Fokoua AR, Kumanwee L, Uyere EG, Emuakpeje TM. Antipsychotic effect of diosgenin in ketamine-induced murine model of schizophrenia: Involvement of oxidative stress and cholinergic transmission. IBRO Neurosci Rep. 2024; 16:86-97. doi: 10.1016/j.ibneur.2023.12.008

[27] Danduga RCSR, Kola PK. Elevated plus maze for assessment of anxiety and memory in rodents. In: Ray SK, editor. Neuroprotection. Methods in Molecular Biology. New York: Humana; 2024. p. 2761. doi: 10.1007/978-1-0716-3662-6_8

[28] Alex EA, Tanko Y, Muhammed K, et al. Modulatory role of lauric acid supplement on lipid peroxidation and some antioxidant enzymes activity in high fat diet, streptozotocin-induced type 2 diabetic male wistar rats. J Afr Assoc Physiol Sci. 2019; 7(1):23-29.

[29] Venâncio C, Félix L, Almeida V, et al. Acute ketamine impairs mitochondrial function and promotes superoxide dismutase activity in the rat brain. Anesth Analg. 2015; 120(2):320-328. doi: 10.1213/ANE.0000000000000539

[30] Jefferson PG, Alex CM, Ana Cristina CC, et al. Profiling of behavioural effects evoked by ketamine and the role of 5HT2 and D2 receptors in ketamine-induced locomotor sensitization in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2020;97:109775. doi: 10.1016/j.pnpbp.2019.109775

[31] Jonathan A, Naomi EM, Alex LW, Emily MJ, Jessica AS. The effects of acute and repeated administration of ketamine on memory, behaviour, and plasma corticosterone levels in female mice. Neuroscience. 2023; 512:99-109. doi: 10.1016/j.neuroscience.2022:12.002

[32] Gabor I, Dirk SF, Johan AD, Gert JTH. Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res Bull. 2006; 69(3):338-345. doi: 10.1016/j.brainresbull.2006.01.010

[33] Sokoloff P, Leriche L, Diaz J, Louvel J, Pumain R. Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: Implications for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol. 2013; 386(2):107-124. doi: 10.1007/s00210-012-0797-0

[34] Suda Y, Uka T. The NMDA receptor antagonist ketamine impairs and delays context-dependent decision making in the parietal cortex. Commun Biol. 2022; 20:5(1): 690. doi: 10.1038/s42003-022-03626-z

[35] Bošković M, Vovk T, Kores Plesničar B, Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol. 2011; 9(2):301-312. doi: 10.2174/157015911795596595

[36] Rawani NS, Chan AW, Dursun SM, Baker GB. The underlying neurobiological mechanisms of psychosis: Focus on neurotransmission dysregulation, neuroinflammation, oxidative stress, and mitochondrial dysfunction. Antioxidants (Basel) 2024; 13(6):709. doi: 10.3390/antiox13060709

[37] Dharmalingam SK, Amirtharaj GJ, Ramachandran A, Korula M. Volatile anesthetic preconditioning modulates oxidative stress and nitric oxide in patients undergoing coronary artery bypass grafting. Ann Card Anaesth. 2021; 24(3):319-326. doi: 10.4103/aca.ACA_130_20

[38] Steurer MP, Steurer MA, Baulig W, et al. Late pharmacologic conditioning with volatile anesthetics after cardiac surgery. Crit Care. 2021; 16(5):R191. doi: 10.1186/cc11676

[39] Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Ying YC. The effect of risperidone treatment on superoxide dismutase in schizophrenia. J Clin Psychopharmacol. 2003; 23(2):128-131.

[40] Zhang XY, Zhou DF, Shen YC, et al. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology. 2012; 62(5-6):1928-1934. doi: 10.1016/j.neuropharm.2011.12.014